SE9502244D0 - A composition and a process for the preparation thereof - Google Patents

A composition and a process for the preparation thereof

Info

Publication number
SE9502244D0
SE9502244D0 SE9502244A SE9502244A SE9502244D0 SE 9502244 D0 SE9502244 D0 SE 9502244D0 SE 9502244 A SE9502244 A SE 9502244A SE 9502244 A SE9502244 A SE 9502244A SE 9502244 D0 SE9502244 D0 SE 9502244D0
Authority
SE
Sweden
Prior art keywords
composition
pct
glass
active agent
plasticizer
Prior art date
Application number
SE9502244A
Other languages
English (en)
Swedish (sv)
Inventor
Aake Lindahl
Original Assignee
Bioglan Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan Ab filed Critical Bioglan Ab
Priority to SE9502244A priority Critical patent/SE9502244D0/xx
Publication of SE9502244D0 publication Critical patent/SE9502244D0/xx
Priority to PCT/SE1996/000806 priority patent/WO1997000670A1/en
Priority to US08/973,902 priority patent/US6083518A/en
Priority to ES96921197T priority patent/ES2118677T3/es
Priority to EP96921197A priority patent/EP0833611B1/en
Priority to AU62473/96A priority patent/AU695622B2/en
Priority to DE69614689T priority patent/DE69614689T2/de
Priority to DK96921197T priority patent/DK0833611T3/da
Priority to CA002225286A priority patent/CA2225286C/en
Priority to DE0833611T priority patent/DE833611T1/de
Priority to JP50378997A priority patent/JP4020331B2/ja
Priority to NZ311208A priority patent/NZ311208A/xx
Priority to PT96921197T priority patent/PT833611E/pt
Priority to AT96921197T priority patent/ATE204466T1/de
Priority to ZA965237A priority patent/ZA965237B/xx
Priority to HK98109537A priority patent/HK1008774A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Processing Of Solid Wastes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE9502244A 1995-06-20 1995-06-20 A composition and a process for the preparation thereof SE9502244D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof
AT96921197T ATE204466T1 (de) 1995-06-20 1996-06-19 Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
DE69614689T DE69614689T2 (de) 1995-06-20 1996-06-19 Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
CA002225286A CA2225286C (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
ES96921197T ES2118677T3 (es) 1995-06-20 1996-06-19 Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.
EP96921197A EP0833611B1 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
AU62473/96A AU695622B2 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
PCT/SE1996/000806 WO1997000670A1 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
DK96921197T DK0833611T3 (da) 1995-06-20 1996-06-19 Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf
US08/973,902 US6083518A (en) 1995-06-20 1996-06-19 Composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
DE0833611T DE833611T1 (de) 1995-06-20 1996-06-19 Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung
JP50378997A JP4020331B2 (ja) 1995-06-20 1996-06-19 ガラス形成性担体に溶解した活性物質からなる組成物及びその製造方法
NZ311208A NZ311208A (en) 1995-06-20 1996-06-19 Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees
PT96921197T PT833611E (pt) 1995-06-20 1996-06-19 Composicao que compreendendo um agente activo dissolvido num veiculo formador de vidro e processo para a sua preparacao
ZA965237A ZA965237B (en) 1995-06-20 1996-06-20 A composition and a process for the preparation thereof
HK98109537A HK1008774A1 (en) 1995-06-20 1998-07-29 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
SE9502244D0 true SE9502244D0 (sv) 1995-06-20

Family

ID=20398685

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof

Country Status (15)

Country Link
US (1) US6083518A (xx)
EP (1) EP0833611B1 (xx)
JP (1) JP4020331B2 (xx)
AT (1) ATE204466T1 (xx)
AU (1) AU695622B2 (xx)
CA (1) CA2225286C (xx)
DE (2) DE833611T1 (xx)
DK (1) DK0833611T3 (xx)
ES (1) ES2118677T3 (xx)
HK (1) HK1008774A1 (xx)
NZ (1) NZ311208A (xx)
PT (1) PT833611E (xx)
SE (1) SE9502244D0 (xx)
WO (1) WO1997000670A1 (xx)
ZA (1) ZA965237B (xx)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4512700B2 (ja) * 2003-06-02 2010-07-28 トーアエイヨー株式会社 アシクロビル含有水溶液製剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
CA2560513A1 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
GB2432528B (en) * 2005-11-29 2011-04-06 Ian Ripley Anti-viral compositions comprising flavanone glycosides and fruit acids
EP2025337B1 (en) * 2006-03-08 2014-09-10 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
RU2423128C2 (ru) * 2006-03-08 2011-07-10 Нихон Нохияку Ко., Лтд. Фармацевтическая композиция для наружного применения
WO2007102243A1 (ja) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. 外用の医薬組成物
AU2007260739A1 (en) 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
KR100721126B1 (ko) 2006-12-28 2007-05-23 (주)바이오앤에이치엔티 모기 기피제 조성물
WO2009031642A1 (ja) 2007-09-05 2009-03-12 Pola Pharma Inc. 医薬組成物
EP2191828B1 (en) * 2007-09-05 2016-08-10 Pola Pharma Inc. Antifungal pharmaceutical composition
WO2009031643A1 (ja) 2007-09-05 2009-03-12 Pola Pharma Inc. 抗真菌組成物
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5421901B2 (ja) * 2008-03-31 2014-02-19 国立大学法人広島大学 エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
CN102256969A (zh) 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
HUE032022T2 (en) 2009-01-09 2017-08-28 Egyt Gyogyszervegyeszeti Gyar Medicinal product with improved effect
JP5654497B2 (ja) * 2009-02-13 2015-01-14 トピカ ファーマシューティカルズ，インコーポレイテッド 抗真菌製剤
JP5688405B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
ES2591004T3 (es) 2010-04-27 2016-11-24 Calcimedica, Inc. Compuestos moduladores del calcio intracelular
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CA2809830C (en) 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN105960404B (zh) 2013-12-05 2019-09-03 药品循环有限责任公司 布鲁顿氏酪氨酸激酶的抑制剂
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
PT3104854T (pt) 2014-02-10 2020-06-26 Respivant Sciences Gmbh Estabilizadores de mastócitos para tratamento de doença pulmonar
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
EP3154338B1 (en) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
MX2017011018A (es) 2015-02-27 2018-01-18 Curtana Pharmaceuticals Inc Inhibicion de la actividad de olig2.
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
JP2019516773A (ja) 2016-05-25 2019-06-20 コンセントリック アナルジジックス，インク． 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールｔｒｐｖ１アゴニストのプロドラッグ
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
KR102605329B1 (ko) 2016-08-26 2023-11-22 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US11382897B2 (en) 2017-11-07 2022-07-12 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
CN111542318A (zh) 2017-11-10 2020-08-14 密歇根大学董事会 Ash1l降解剂及用其进行治疗的方法
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
JP2021532183A (ja) 2018-07-27 2021-11-25 コンセントリック アナルジェジクス，インク． フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ
WO2020044114A2 (en) 2018-08-29 2020-03-05 Ftf Pharma Private Limited Methotrexate pharmaceutical composition
WO2020046466A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
EP3870227B1 (en) * 2018-10-24 2022-12-21 SeraNovo B.V. Deep eutectic solvent platform for oral pharmaceutical formulations
NL2021864B1 (en) * 2018-10-24 2020-05-13 Seranovo B V Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
US10925904B2 (en) 2018-11-06 2021-02-23 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
MX2021011081A (es) 2019-03-15 2022-01-18 Unicycive Therapeutics Inc Derivados de nicorandil.
CA3185209A1 (en) 2020-07-10 2021-01-27 Alyssa WINKLER Gas41 inhibitors and methods of use thereof
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
US20230120115A1 (en) 2021-08-11 2023-04-20 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33221A (en) * 1861-09-03 Improvement in soap
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
USRE33221E (en) 1982-04-29 1990-05-22 American Dental Association Health Foundation Dental restorative cement pastes
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0319988A1 (en) * 1987-12-09 1989-06-14 Showa Denko Kabushiki Kaisha External dermatological composition
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
JP4020331B2 (ja) 2007-12-12
PT833611E (pt) 2002-01-30
JPH11508250A (ja) 1999-07-21
WO1997000670A1 (en) 1997-01-09
HK1008774A1 (en) 1999-05-21
ZA965237B (en) 1997-01-09
CA2225286A1 (en) 1997-01-09
DE69614689T2 (de) 2002-06-27
ATE204466T1 (de) 2001-09-15
AU6247396A (en) 1997-01-22
EP0833611B1 (en) 2001-08-22
ES2118677T1 (es) 1998-10-01
ES2118677T3 (es) 2001-10-16
EP0833611A1 (en) 1998-04-08
US6083518A (en) 2000-07-04
NZ311208A (en) 1999-03-29
CA2225286C (en) 2003-06-10
DK0833611T3 (da) 2001-10-08
DE833611T1 (de) 1999-01-07
AU695622B2 (en) 1998-08-20
DE69614689D1 (de) 2001-09-27

Similar Documents

Publication Publication Date Title
SE9502244D0 (sv) A composition and a process for the preparation thereof
DE69434626D1 (de) Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
NO964939D0 (no) Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte
FI103091B1 (fi) Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi
DK0790824T3 (da) 2,2-dichloralkancarboxylsyrer, fremgangsmåde til fremstilling deraf, lægemidler indeholdende disse og anvendelse af disse lægemidler til behandling af insulinresistens
BR9408377A (pt) Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto
IS3966A (is) Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine
NO973646L (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
ATE237316T1 (de) Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
NZ508074A (en) Biologically active compositions, and methods for their preparation, comprising a carrier matrix supersaturated with active agent
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
ATE19472T1 (de) Verwendung von 5-phenyl-1,4-benzodoazepinen zur herstellung von analgetisch wirksamen pharmazeutischen zubereitungen.
EP0305194A3 (en) Veterinary composition
GT198700016A (es) Procedimiento para la preparacion de n benzoil -n'-fenilu--reas.
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them